EVIdence Based TreAtment - Heart Failure (EVITA-HF)

NCT01057004 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4560

Last updated 2016-06-24

No results posted yet for this study

Summary

EVITA should function as an idea supplier and should coordinate possible future studies. Other important tasks of the register are: (i) the establishment of recommendations for an optimal medicinal therapy (OMT) as well as for ICD- and CRT-treatment; (ii) the establishment of quality assurance measures, including monitoring of new therapy.

Conditions

Sponsors & Collaborators

  • Vifor Pharma

    collaborator INDUSTRY
  • Stiftung Institut fuer Herzinfarktforschung

    lead OTHER

Principal Investigators

  • Jochen Senges, MD · Stiftung Institut für Herzinfarktforschung

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01057004 on ClinicalTrials.gov